Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>SNDX-5613

SNDX-5613

SNDX-5613 Structure
SNDX-5613 structure
CAS No.
2169919-21-3
Chemical Name:
SNDX-5613
Synonyms
Revumenib;SNDX-5613;SNDX-5613 SNDX5613;SNDX-5613 (Revumenib);SNDX-5613, 10 mM in DMSO;acute,Leukemia,inhibit,lymphoblastic,Epigenetic Reader Domain,Inhibitor,AML,Menin,ALL,SNDX 5613,SNDX-5613,SNDX5613,MLL,myeloid;N-Ethyl-2-((4-(7-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide;N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide;N-Ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)benzamide;Benzamide, N-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)-
CBNumber:
CB47244410
Molecular Formula:
C32H47FN6O4S
Molecular Weight:
630.82
MDL Number:
MFCD32701940
MOL File:
2169919-21-3.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-07-17 09:03:53
Product description Number Pack Size Price
SNDX-5613 ≥98% 40758 5mg $131
SNDX-5613 ≥98% 40758 10mg $249
SNDX-5613 ≥98% 40758 25mg $459
SNDX-5613 ≥98% 40758 50mg $786
SNDX-5613 ULD91921 25mg $1164.25
Request For Quotation

SNDX-5613 Properties

Boiling point 739.1±70.0 °C(Predicted)
Density 1.28±0.1 g/cm3(Predicted)
solubility DMSO:30.0(Max Conc. mg/mL);47.56(Max Conc. mM)
pka 11.10±0.40(Predicted)
form Solid
color White to off-white
InChIKey FRVSRBKUQZKTOW-YOCNBXQISA-N
SMILES C(N(CC)C(C)C)(=O)C1=CC(F)=CC=C1OC1=CN=CN=C1N1CC2(CCN(C[C@@H]3CC[C@@H](NS(CC)(=O)=O)CC3)CC2)C1
FDA UNII LZ0M43NNF2

SAFETY

Risk and Safety Statements

Symbol(GHS)  Exclamation Mark (GHS07)
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319
Precautionary statements  P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

SNDX-5613 price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 40758 SNDX-5613 ≥98% 2169919-21-3 5mg $131 2026-04-30 Buy
Cayman Chemical 40758 SNDX-5613 ≥98% 2169919-21-3 10mg $249 2026-04-30 Buy
Cayman Chemical 40758 SNDX-5613 ≥98% 2169919-21-3 25mg $459 2026-04-30 Buy
Cayman Chemical 40758 SNDX-5613 ≥98% 2169919-21-3 50mg $786 2026-04-30 Buy
Biosynth ULD91921 SNDX-5613 2169919-21-3 25mg $1164.25 2026-06-05 Buy
Product number Packaging Price Buy
40758 5mg $131 Buy
40758 10mg $249 Buy
40758 25mg $459 Buy
40758 50mg $786 Buy
ULD91921 25mg $1164.25 Buy

SNDX-5613 Chemical Properties,Uses,Production

Uses

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].

in vivo

Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts[1].

References

[1] A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).

SNDX-5613 Preparation Products And Raw materials

Raw materials

Preparation Products

SNDX-5613 Suppliers

Global( 104)Suppliers
Supplier Tel Email Country ProdList Advantage
BOC Sciences 		+1-631-485-4226 inquiry@bocsci.com United States 19935 58
CONIER CHEM AND PHARMA LIMITED 		sales@conier.com China 49906 58
TargetMol Chemicals Inc. 		+1-781-999-5354; +1-00000000000 marketing@targetmol.com United States 32431 58
Zhejiang J&C Biological Technology Co.,Limited 		+1-2135480471 sales@sarms4muscle.com China 10378 58
TargetMol Chemicals Inc. 		+1-781-999-5354; support@targetmol.com United States 38999 58
Zibo Hangyu Biotechnology Development Co., Ltd 		+86-0533-2185556 +86-15965530500 nickzhang@hangyubiotech.com China 9930 58
Aladdin Scientific 		tp@aladdinsci.com United States 54746 58
Suzhou ARTK Medchem Co., Ltd. 		+86-18168183658 sales1@artkmedchem.com China 39007 58
Shaanxi Dideu New Materials Co. Ltd 		18192503167 1036@dideu.com China 13339 58
NANJING YINGWEN BIOTECHNOLOGY CO LTD 		+86-13382787392 sales@aeechem.com China 10001 58
Supplier Advantage
BOC Sciences 		58
CONIER CHEM AND PHARMA LIMITED 		58
TargetMol Chemicals Inc. 		58
Zhejiang J&C Biological Technology Co.,Limited 		58
TargetMol Chemicals Inc. 		58
Zibo Hangyu Biotechnology Development Co., Ltd 		58
Aladdin Scientific 		58
Suzhou ARTK Medchem Co., Ltd. 		58
Shaanxi Dideu New Materials Co. Ltd 		58
NANJING YINGWEN BIOTECHNOLOGY CO LTD 		58

View Lastest Price from SNDX-5613 manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Revumenib pictures 2026-07-17 Revumenib
2169919-21-3
 $74.00-245.00 99.77% 10g TargetMol Chemicals Inc.
Revumenib pictures 2026-07-17 Revumenib
2169919-21-3
 $74.00-245.00 99.77% 10g TargetMol Chemicals Inc.
SNDX-5613 pictures 2026-07-06 SNDX-5613
2169919-21-3
 1KG 98% 1000kg Shaanxi Dideu New Materials Co. Ltd
  • Revumenib pictures
  • Revumenib
    2169919-21-3
  • $74.00-245.00
  • 99.77%
  • TargetMol Chemicals Inc.
  • Revumenib pictures
  • Revumenib
    2169919-21-3
  • $74.00-245.00
  • 99.77%
  • TargetMol Chemicals Inc.
  • SNDX-5613 pictures
  • SNDX-5613
    2169919-21-3
  • $0.00
  • 98%
  • Shaanxi Dideu New Materials Co. Ltd

SNDX-5613 Spectrum

SNDX-5613(2169919-21-3)1HNMR

2169919-21-3(SNDX-5613)Related Search:

SNS-062 PF-04929113 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide hydrochloride N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea
VTP50469 mesylate

1of2

SNDX-5613 acute,Leukemia,inhibit,lymphoblastic,Epigenetic Reader Domain,Inhibitor,AML,Menin,ALL,SNDX 5613,SNDX-5613,SNDX5613,MLL,myeloid Benzamide, N-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)- SNDX-5613 SNDX5613 N-Ethyl-2-((4-(7-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide SNDX-5613, 10 mM in DMSO N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide N-Ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)benzamide SNDX-5613 (Revumenib) Revumenib N-Ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)benzamide (ACI) 2169919-21-3